Invasive fungal disease in patients from five hospitals in the Valparaiso Region, Chile. 2004 to 2009;Enfermedad fúngica invasora en pacientes de cinco hospitales de la región de valparaíso, Chile. 2004 a 2009

Revista Chilena de Infectologia

Volumn 28, Issue 2, 2011, Pages 123-129

  Rodrigo Cruz, Ch ^a,b,c   Eduardo Piontelli, L ^a  

^a UNIVERSIDAD DE VALPARAÍSO   (Chile)

^b Hospital San Camilo   (Chile)

^c HOSPITAL CARLOS VAN BUREN   (Chile)

Author keywords

Aspergillus; Candida; Immunocompromise; Invasive fungal disease; Mortality

Indexed keywords

ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHILE; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FUNGEMIA; FUNGUS; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MYCOSIS; NEWBORN; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; CHILE; FEMALE; FUNGEMIA; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 79957826241     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: 10.4067/S0716-10182011000200004     Document Type: Article

References (52)

1. Ascioglu S, Rex JH, Dc Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An International Consensus. Clin Infect Dis 2002; 34: 7-14.
2. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15 year period (1989-2003). Hematological 2006; 91: 986-989.
3. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009;48: 1695-1703.
4. Garcia-Ruiz JC, Amutio E, Ponton J. Infección fúngica invasora en pacientes inmunodeficientes. Rev Iberoam Micol 2004; 21:55-62.
5. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006; 55: 809-818.
6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
7. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
8. Husain S, Alexander BD, Munoz P, Avery RK, Houston S, Pruett T, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003;37:221-229.
9. Pontón J, Quindós G, editores. Micosis invasoras en los pacientes oncohematológicos. Guia de bolsillo. Sociedad española de Micología. 2009.
10. Pagano L, Caira M, Nosari A, Van Lint M T, Candoni A, Offidani M, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nolle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-1170.
11. Maertens J, Verhaegen J, Lagrou K. Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolongued neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-1610.
12. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259.
13. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16: 607-612.
14. Silva V, Díaz MC, Febré N y red de diagnóstico en micologfa médica. Vigilancia de la resistencia de levaduras a antifungicos. Rev Chil Infect 2002; 19: 149-156.
15. Rabagliati R, Fuentes G, Guzmán AM, Orellana E, Oporto J, Aedo I, et al. Enfermedad fúngica invasora en pacientes hemato-oncológicos y receptores de trasplante de precursors hematopoyéticos bajo la perspectiva de los criterios diagnóstics EORTC/MSG. Rev Chil Infect 2009; 26: 212-219.
16. Santolaya ME, Rabagliati R, Bidart T, Paya E, Guzmán AM, Morales R, et al. Consenso Manejo racional del paciente con cáncer, neutropenia y fiebre. Rev Chil Infect 2005; 22: 79-113.
17. De Pauw B, Walsh TJ, Donnelly P, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
18. Borges M. Actualización sobre el tratamiento de las infecciones fúngicas graves. Rev Esp Quimioter 2008; 21: 14-25.
19. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
20. De hoog GS, Guarro J, Gene J, Figueras MJ. Atlas of clinical fungi: Centralbureau voor Schilmmelcultures/Universitat Rovira y Virgili. Baarn and Delf, The Netherlands, Universitat Rovira y Virgili, Reus, Spain, 2000.
21. Piontelli E. Aportes morfotaxonómicos en el género Aspergillus Link: claves para las especies ambientales y clinicas más comunes. Bol Micol 2008; 23:49-66.
22. Gadea I, Cuenca-Estrella M, Martin E, Pemán J, Pontón J, Rodríguez-Tudela JL. Procedimientos de diagnóstico microbiológico de las micosis y estudios de sensibilidad a los antifúngicos. Enferm Infec Microbiol Clin 2007; 25: 336-340.
23. National Committee for Clinical Laboratory Standards. Methods for antifungal disk diffusion susceptibility testing of yeasts: Approved standard M44-A. NCCLS, Wayne, PA, USA. 2004.
24. Tapia C. Actualizacion en pruebas de susceptibilidad antifungica. Rev Chil Infect 2009; 26: 144-150.
25. Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol 2007;45:569-587.
26. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000; 79: 250-260.
27. Comely O, Maertens J, Winston D, Perfect J, Ullmann A, Walsh T, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
28. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
29. Walsh T, Hiemenz J, Seibel N, Perfect J, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
30. Cornejo M, López J, Navarro S, García de OD, Patiño P. Caracterización clínico-molecular de la enfermedad granulomatosa crónica autosómica recesiva causada por déficit de p47-phox. Rev Med Chile 2000; 128:490-498.
31. Pérez A, Contreras AM, Zolezzi RP, Cruz C, Fierro C, Faundez C, et al. Infección por hongos en catéteres venosos centrales. Rev Chil Pediatr 2002; 73: 489-494.
32. Coyle E. Invasive candidiasis and the utility of antifungal susceptibility testing in the ICU. J PharmPract 2010; 23: 33-37.
33. Tiraboschi IN, Bennett JE, Kauffman CA, Rex JH, Girmenia C, Sobel JD, et al. Deep Candida infections in the neutropenic and non-neutropenic host: an ISHAM symposium. Med Mycol 2000; 38: 199-204.
34. Wheat J. Endemic mycosis in AIDS: a clinical review. Clin Microbiol Rev 1995; 8: 146-159.
35. González A, Tobón AM. Infecciones micóticas oportunistas en pacientes con VIH/SIDA. Infect 2006; 10: 279-287.
36. Cruz R, Opazo H, Barthel E, Campos S, Piontelli E. Reporte clinico: histoplasmosis diseminada aloctona en un paciente con sindrome de inmunodeficiencia adquirida. Bol Micol 2006;21:77-84.
37. Pinel C, Fricker-Hidalgo H, Lebeau B, Garban F, Hamidfar R, Ambroise-Thomas P, et al. Detection of circulating Aspergillus-fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003;41:2184-2186.
38. Ansorg R, van der Boom R, Rath PM. Detection of Aspergillus' galactomannan antigen in foods and antibiotics. Mycoses 1997; 40: 353-357.
39. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, et al. Voriconazole versus- amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415.
40. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
41. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52: 197-205.
42. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23:317-322.
43. Upton A, Kirby K, Carpenter P, Boeckh M, Marr IC. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
44. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20(3): 485-506.
45. Playford EG, Sorrell TC. Optimizing therapy for Candida infections. Semin Respir Crit Care Med 2007; 28: 678-688.
46. St-Germain G, Laverdiere M, Pelletier R, Bourgault A M, Libman M, Lemieux C, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2 year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39: 949-953.
47. Gómez J, Garcia-Vazquez E, Espinosa C, Ruiz J, Canteras M, Hernández-Torres A, et al. Nosocomial candidemia at a general hospital: The change of epidemiological and clinical characteristics. A comparative study of 2 cohorts (1993-1998 versus 2002-2005). Rev Iberoam Micol 2009; 26: 184-188.
48. Aroca TS, Piontelli LE, Cruz Ch R. Case report: Trichoderma longibrachiatum infection in a paediatric patient with peritoneal dialysis. Bol Micol 2004; 19: 13-17.
49. Tanis BC, Van derpijl H, Van Ogtrop ML, Kibbelaar RE, Chang PC. Fatal fungal peritonitis by Trichoderma longibrachiatum complicating peritoneal dialysis. Nephrol Dial Transplant 1995; 10: 114-116.
50. Abril V, Ortega E, Segarra P, Pedro F, Sabater V, Herrera A. Rhinocerebral mucormycosis in a patient with AIDS: A complication of diabetic ketoacidosis following pentamidine therapy. Clin Infect Dis 1996; 23: 845-846.
51. González C, Rinaldi M, Sugar A. Zygomycosis. Infect Dis Clin North Am 2002; 16: 895-914.
52. Bravo M, Ferrer S, Etchard M, Trujillo S. Mucormicosis rinocerebral. Comunicacion de 4 casos. Rev Med Chile 1999; 127: 712-718.